title: Efficacy of temozolomide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma.
abstract: OBJECTIVE
  To compare results of treatment with temozolomide or dacarbazine, in combination with an anthracycline, in dogs with relapsed or refractory lymphoma.
  
  
  METHODS
  Nonrandomized, controlled clinical trial.
  
  
  METHODS
  63 dogs with relapsed or refractory lymphoma.
  
  
  METHODS
  Chemotherapy was administered in 21-day cycles. A combination of temozolomide and an anthracycline (doxorubicin or dactinomycin) was administered to 21 dogs and a combination of dacarbazine and an anthracycline was administered to 42 dogs. Efficacy and toxicoses were assessed. Results-Thirteen of the 18 (72%) dogs treated with the temozolomide-anthracycline combination and 25 of the 35 (71%) dogs treated with the dacarbazine-anthracycline combination had a complete or partial response. Median duration of response to rescue chemotherapy was 40 days (range, 0 to 217 days) for dogs in the temozolomide group and 50 days (range, 0 to 587 days) for dogs in the dacarbazine group. The incidence of high-grade hematologic toxicoses was significantly higher among dogs in the dacarbazine group than among dogs in the temozolomide group, but the incidence of gastrointestinal tract toxicoses was not significantly different between groups. There were no significant differences between groups in regard to proportion of dogs with a complete or partial response, duration of response to rescue chemotherapy, survival time following rescue chemotherapy, or overall survival time.
  
  
  CONCLUSIONS
  Both combinations had promise in the treatment of dogs with relapsed or refractory lymphoma, although administration of temozolomide was more convenient than administration of dacarbazine and caused fewer hematologic toxicoses.
authors: Center for Comparative Oncology, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824, USA.
authors: Nikolaos G
authors: NG
authors: Dervisis
authors: Pedro A
authors: PA
authors: Dominguez
authors: Luminita
authors: L
authors: Sarbu
authors: Rebecca G
authors: RG
authors: Newman
authors: Casey D
authors: CD
authors: Cadile
authors: Christine N
authors: CN
authors: Swanson
authors: Barbara E
authors: BE
authors: Kitchell
mesh_terms: D000818:Animals; D018943:Anthracyclines / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D019008:Drug Resistance, Neoplasm; D005260:Female; D008223:Lymphoma / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D016019:Survival Analysis; D000077204:Temozolomide; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D003606:Dacarbazine; D000077204:Temozolomide